1. identification of 3, 4-disubstituted pyridine derivatives as novel cdk8 inhibitors, haochao zhang#, liandong jing#, man liu, masuo goto, fangang lai, xiao liu, li sheng, ying yang, yajun yang, yan li, xiaoguang chen, kuo-hsiung lee, zhiyan xiao*, eur. j. med. chem. 2021, 223: 113634.
2. design, synthesis and biological evaluation of dipeptides as novel non-covalent 20s proteasome inhibitors, ya-jun yang, ke wang, ying yang, fang-fang lai, xiao-guang chen, zhiyan xiao*, j. asian nat. prod. res. 2021, 23 (5): 436–451.
3. design, synthesis and biological evaluation of triaryl compounds as novel 20s proteasome inhibitors, yajun yang, ke wang, bo wu, ying yang, fangfang lai, xiaoguang chen, zhiyan xiao*, bioorg. med. chem. lett. 2020, 30 (21): 127508.
4. identification of potential indoleamine 2, 3-dioxygenase 1 (ido1) inhibitors by an fbg-based 3d qsar pharmacophore model, lu zhang, fangfang lai, xiaoguang chen, zhiyan xiao*, j. mol. graph. model. 2020, 99: 107628.
5. identification of xanthine oxidase inhibitors through hierarchical virtual screening, ying yang, lei zhang, jinying tian, fei ye, zhiyan xiao*, rsc adv., 2020, 10: 27752.
6. identification of natural products as selective ptp1b inhibitors via virtual screening, ying yang, jin-ying tian, fei ye, zhiyan xiao*, bioorg. chem. 2020, 98: 103706.
7. carboxylic acid promoted single-step indole construction from simple anilines and ketones via aerobic cross-dehydrogenative coupling, long ren, guanglei nan, yongcheng wang, zhiyan xiao*, j. org. chem. 2018, 83 (23): 14472-14488.
8. novel benzamido derivatives as ptp1b inhibitors with anti-hyperglycemic and lipid-lowering efficacy, yanbo tang#, xiaolin zhang#, zheng chen, wenwen yin, guanglei nan, jinying tian, fei ye, zhiyan xiao, acta pharm. sin. b 2018, 8 (6): 919–932.
9. discovery of novel cdk inhibitors via scaffold hopping from can508, liandong jing, yanbo tang, zhiyan xiao, bioorg. med. chem. lett. 2018, 28 (8): 1386–1391.
10. sar study on n2,n4-disubstituted pyrimidine-2,4-diamines as effective cdk2/cdk9 inhibitors and antiproliferative agents, liandong jing, yanbo tang, masuo goto, kuo-hsiung lee, zhiyan xiao, rsc adv. 2018, 8 (22): 11871–11885.
11. design, synthesis and biological evaluation of novel indolin-2-ones as potent anticancer compounds, andong zhou, lei yan, fangfang lai, xiaoguang chen, masuo goto, kuo-hsiung lee, zhiyan xiao, bioorg. med. chem. lett. 2017, 27 (15): 3326-3331.
12. strategies for the optimization of natural leads to anticancer drugs or drug candidates, zhiyan xiao, susan l. morris-natschke, kuo-hsiung lee, med. res. rev. 2016, 36 (1): 32-91.
13. receptor-based 3d-qsar in drug design: methods and applications in kinase studies, cheng fang, zhiyan xiao*, curr. top. med. chem.2016, 16 (13): 1463-1477.